Kazuo Okemoto1, Kazue Kasai, Benjamin Wagner, Amy Haseley, Hans Meisen, Chelsea Bolyard, Xiaokui Mo, Allison Wehr, Amy Lehman, Soledad Fernandez, Balveen Kaur, E Antonio Chiocca. 1. Authors' Affiliations: Dardinger Center for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Cancer Hospital/Solove Research Institute/Comprehensive Cancer Center and Wexner Medical Center; Center for Biostatistics, The Ohio State University, Columbus, Ohio; and Department of Neurosurgery Institute for the Neurosciences at the Brigham, Brigham and Women's/Faulkner Hospital and Center for Neuro-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
PURPOSE: Oncolytic viruses (OV) based on herpes simplex virus type 1 (HSV1) are being used in clinical trials for a variety of cancers. The OV, rQNestin34.5, uses a nestin promoter/enhancer to selectively drive robust viral replication in malignant glioma cells. We have discovered that this promoter becomes extensively methylated in infected glioma cells, reducing OV efficacy. EXPERIMENTAL DESIGN: We used demethylating drugs [5-azacytidine (5-Aza)], decitabine, or valproic acid (VPA) in both in vitro and in vivo malignant glioma models to determine if they improved the efficacy of rQNestin34.5 therapy. RESULTS: The use of demethylating agents, such as 5-Aza, improved OV replication and tumor cell lysis in vitro and, in fact, synergized pharmacologically on Chou-Talalay analysis. In vivo, the combination of the demethylating agents, 5-Aza or decitabine, with rQNestin34.5 significantly prolonged the survivorship of athymic mice harboring intracranial human glioma xenografts over single agent alone. CONCLUSION: These results, thus, provide further justification for the exploration of demethylating agents when combined with the OV, rQNestin34.5, in preclinical therapeutics and, possibly, clinical trials for malignant glioma.
PURPOSE: Oncolytic viruses (OV) based on herpes simplex virus type 1 (HSV1) are being used in clinical trials for a variety of cancers. The OV, rQNestin34.5, uses a nestin promoter/enhancer to selectively drive robust viral replication in malignant glioma cells. We have discovered that this promoter becomes extensively methylated in infected glioma cells, reducing OV efficacy. EXPERIMENTAL DESIGN: We used demethylating drugs [5-azacytidine (5-Aza)], decitabine, or valproic acid (VPA) in both in vitro and in vivo malignant glioma models to determine if they improved the efficacy of rQNestin34.5 therapy. RESULTS: The use of demethylating agents, such as 5-Aza, improved OV replication and tumor cell lysis in vitro and, in fact, synergized pharmacologically on Chou-Talalay analysis. In vivo, the combination of the demethylating agents, 5-Aza or decitabine, with rQNestin34.5 significantly prolonged the survivorship of athymic mice harboring intracranial humanglioma xenografts over single agent alone. CONCLUSION: These results, thus, provide further justification for the exploration of demethylating agents when combined with the OV, rQNestin34.5, in preclinical therapeutics and, possibly, clinical trials for malignant glioma.
Authors: Krista A Van Nifterik; Jaap Van den Berg; Ben J Slotman; M Vincent M Lafleur; Peter Sminia; Lukas J A Stalpers Journal: J Neurooncol Date: 2011-10-26 Impact factor: 4.130
Authors: George Reid; Raphaël Métivier; Chin-Yo Lin; Stefanie Denger; David Ibberson; Tomi Ivacevic; Heike Brand; Vladimir Benes; Edison T Liu; Frank Gannon Journal: Oncogene Date: 2005-07-21 Impact factor: 9.867
Authors: Chelsea Bolyard; Ji Young Yoo; Pin-Yi Wang; Uksha Saini; Kellie S Rath; Timothy P Cripe; Jianying Zhang; Karuppaiyah Selvendiran; Balveen Kaur Journal: Clin Cancer Res Date: 2014-10-07 Impact factor: 12.531